Depemokimab (2) – Exdensur®
Chronic rhinosinusitis with nasal polyps
Characteristics
| Start date | 01.04.2026 – Marketing authorisation: 12.02.2026 |
|---|---|
| Resolution | 01.10.2026 |
| INN | Depemokimab |
| Brand name | Exdensur® |
| Pharm. company | GlaxoSmithKline GmbH & Co. KG |
| G-BA Procedure ID | D-1311 |
| ATC code | R03DX12 Other systemic drugs for obstructive airway diseases (R03DX) |
| Therapeutic area | Respiratory system diseases |
| Reason for procedure | Initial assessment |
Studies and Results
- Clinical trials
- In the dossier, the pharmaceutical manufacturer presents the data from the 52-week, placebo-controlled ANCHOR-1 and ANCHOR-2 trials.
Adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) in whom adequate disease control has not been achieved through treatment with systemic corticosteroids and/or surgery
- For adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), in whom adequate disease control has not been achieved through treatment with systemic corticosteroids and/or surgical intervention, the additional benefit of depemokimab as an add-on therapy to intranasal corticosteroids is not proven.
- No direct comparative data are available for depemokimab against the appropriate comparator therapy.
Courtesy translation only, please refer to the German original.
Associated procedures
| Depemokimab (2) | Exdensur® | GlaxoSmithKline GmbH & Co. KG | Chronic rhinosinusitis with nasal polyps | 23,500 | 100% additional benefit not proven | |
| Depemokimab (1) | Exdensur® | GlaxoSmithKline GmbH & Co. KG | Bronchial asthma, ≥ 12 years | 30,800–62,400 | 100% additional benefit not proven |
<< List of all resolutions